AHA Secondary_Prev_Update_May2006-1

AHA Secondary_Prev_Update_May2006-1 - 2 AHA/ACC Guidelines...

Info iconThis preview shows pages 1–7. Sign up to view the full content.

View Full Document Right Arrow Icon

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: 2 AHA/ACC Guidelines for Secondary AHA/ACC Guidelines for Secondary Prevention for Patients with Coronary Prevention for Patients with Coronary and Other Atherosclerotic Vascular and Other Atherosclerotic Vascular Disease: 2006 Update Disease: 2006 Update Gregg C. Fonarow, MD and Sidney Smith Jr, MD on behalf of the Secondary Prevention Writing Group 3 Introduction Introduction This slide set was adapted from the AHA/ACC Secondary Prevention for Patients with Coronary and Other Atherosclerotic Vascular Disease: 2006 Update The full-text guidelines are available on the Web sites of the AHA ( www.americanheart.org ) and the ACC (www.acc.org) Circulation 2006;113:2363-2372 and J Am Coll Cardiol 2006;47:2130-2139 4 Introduction Introduction Since the 2001 update of the AHA/ACC consensus statement on secondary prevention, important evidence from clinical trials has emerged that further supports and broadens the merits of aggressive risk reduction therapies This growing body of evidence confirms that aggressive comprehensive risk factor management improves survival, reduces recurrent events and the need for interventional procedures, and improves the quality of life The secondary prevention patient population includes those with established coronary and other atherosclerotic vascular disease, including peripheral arterial disease, atherosclerotic aortic disease and carotid artery disease. 5 AHA Secondary Prevention for Patients with AHA Secondary Prevention for Patients with Coronary Artery and Other Atherosclerotic Coronary Artery and Other Atherosclerotic Vascular Disease Writing Committee Members Vascular Disease Writing Committee Members Sidney C. Smith, Jr, MD; Jerilyn Allen, RN, ScD; Steven N. Blair, Sidney C. Smith, Jr, MD; Jerilyn Allen, RN, ScD; Steven N. Blair, PED; Robert O. Bonow, MD; Lawrence M. Brass, MD; Gregg C. PED; Robert O. Bonow, MD; Lawrence M. Brass, MD; Gregg C. Fonarow, MD; Scott M. Grundy, MD, PhD; Loren Hiratzka, MD ; Fonarow, MD; Scott M. Grundy, MD, PhD; Loren Hiratzka, MD ; Daniel Jones, MD; Harlan M. Krumholz, MD; Lori Mosca, MD, PhD, Daniel Jones, MD; Harlan M. Krumholz, MD; Lori Mosca, MD, PhD, MPH; Richard C. Pasternak, MD*; Thomas Pearson, MD, MPH, MPH; Richard C. Pasternak, MD*; Thomas Pearson, MD, MPH, PhD; Marc A. Pfeffer, MD, PhD; Kathryn A. Taubert, PhD PhD; Marc A. Pfeffer, MD, PhD; Kathryn A. Taubert, PhD * Dr. Pasternak withdrew from the Writing Group on June 22nd, 2004, when he accepted an offer of employment as Vice President, Clinical Research, Cardiovascular and Atherosclerosis at Merck Research Laboratories. Circulation 2006;113:2363-2372 and J Am Coll Cardiol 2006;47:2130-2139 6 Class I Benefit >>> Risk Procedure or treatment SHOULD be performed or administered Class IIa Benefit >> Risk Additional studies with focused objectives needed IT IS REASONABLE to perform procedure or administer treatment Class IIb Benefit Risk Additional studies with broad objectives needed; Additional registry data would...
View Full Document

Page1 / 75

AHA Secondary_Prev_Update_May2006-1 - 2 AHA/ACC Guidelines...

This preview shows document pages 1 - 7. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online